Heterodimeric four helix bundle cytokines
AssigneeZymoGenetics, Inc.
InventorsJames West, Stacey Tannheimer
Life of this patent
Estimating the term…
Abstract
Heterodimeric proteins comprising two helical bundle cytokines are disclosed. One of the polypeptides comprises zsig81 and a second polypeptide which comprises either p19 (aka IL-12A) or p35 (aka IL-12A). The proteins may be produced as fusion proteins or expressed as a single chain. The heterdimeric protein comprising zsig81 and p19 is designated zcyto33f2 and the heterodimeric protein comprising zsig81 and p35 is designated zcyto35f2. Zcyto33f2 and zcyto35f2 proteins are associated with epithelial cell types, including lung and gut epithelium, and may play a role in physiological conditions such as inflammation.
Claims7
A method of treating an inflammatory disease comprising administering to a subject a therapeutically effective amount of a protein selected from the group consisting of:
- (a) a sequence of amino acid residues 1 to 156 as shown in SEQ ID NO:
- 2 and a second polypeptide comprises a sequence of amino acid residues as shown in SEQ ID NO:
- 3 or SEQ ID NO:
- 4;
- (b) a sequence of amino acid residues 6 to 156 as shown in SEQ ID NO:
- 2 and a second polypeptide comprises a sequence of amino acid residues as shown in SEQ ID NO:
- 3 or SEQ ID NO:
- 4;
- and
- (c) a sequence of amino acid residues 21 to 156 as shown in SEQ ID NO:
- 2 and a second polypeptide comprises a sequence of amino acid residues as shown in SEQ ID NO:
- 3 or SEQ ID NO:
- 4.
A method of treating an autoimmune disease comprising administering to a subject a therapeutically effective amount of a protein selected from the group consisting of:
- (a) a sequence of amino acid residues 1 to 156 as shown in SEQ ID NO:
- 2 and a second polypeptide comprises a sequence of amino acid residues as shown in SEQ ID NO:
- 3 or SEQ ID NO:
- 4;
- (b) a sequence of amino acid residues 6 to 156 as shown in SEQ ID NO:
- 2 and a second polypeptide comprises a sequence of amino acid residues as shown in SEQ ID NO:
- 3 or SEQ ID NO:
- 4;
- and
- (c) a sequence of amino acid residues 21 to 156 as shown in SEQ ID NO:
- 2 and a second polypeptide comprises a sequence of amino acid residues as shown in SEQ ID NO:
- 3 or SEQ ID NO:
- 4.
A method of stimulating or expanding T regulatory cells in a subject with an autoimmune or inflammatory disease comprising administering a therapeutically effective amount of a protein selected from the group consisting of:
- (a) a sequence of amino acid residues 1 to 156 as shown in SEQ ID NO:
- 2 and a second polypeptide comprises a sequence of amino acid residues as shown in SEQ ID NO:
- 3 or SEQ ID NO:
- 4;
- (b) a sequence of amino acid residues 6 to 156 as shown in SEQ ID NO:
- 2 and a second polypeptide comprises a sequence of amino acid residues as shown in SEQ ID NO:
- 3 or SEQ ID NO:
- 4;
- and
- (c) a sequence of amino acid residues 21 to 156 as shown in SEQ ID NO:
- 2 and a second polypeptide comprises a sequence of amino acid residues as shown in SEQ ID NO:
- 3 or SEQ ID NO:
- 4.
Dependencies are inferred from the claim text.